20 articles
A multinational study finds 56% of genetically diagnosed infants with epilepsy have variants potentially amenable to antisense oligonucleotide treatment.
Scientists used stem cell-derived vesicles to deliver light-activated gene therapy to the brain without surgery, reversing cognitive decline in Alzheimer's mice.
Researchers combined ultrasound with gene therapy to treat Leigh syndrome, significantly extending survival in mouse models.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
New peptide delivery system restores brain connections and memory function in Alzheimer's models, offering hope for treating cognitive decline.
New gene therapy zorevunersen dramatically reduced seizures in children with severe Dravet syndrome epilepsy while improving quality of life.
A molecule called OLE restores microglia's protective function, reducing amyloid plaques and improving memory in animal models.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
Researchers turned ordinary brain cells into plaque-clearing machines, reducing Alzheimer's amyloid by half in mice with one treatment.
Breakthrough antisense therapy demonstrates sustained benefits for rare genetic form of ALS in extended clinical trial.
Overexpressing Sox9 in brain support cells triggers plaque cleanup and protects cognition in Alzheimer's mouse models.
OSK gene therapy targeting engram neurons restored memory to youthful levels in aged mice and Alzheimer's models, reversing senescence hallmarks.
Microglia package healthy mitochondria into vesicles and deliver them to astrocytes, sharply reducing cognitive decline in tau-pathology mice.
New study identifies KCTD20 gene suppression as a potential therapeutic target for clearing harmful tau proteins in neurodegenerative diseases.
New research reveals combined treatments targeting multiple brain pathways outperform traditional single-drug strategies for Alzheimer's disease.
A boy with PLCB1-related epileptic encephalopathy showed improved seizure control and stabilized brain atrophy after high-dose enteral myo-inositol supplementation.
New research reveals how TSC2 mutations suppress translation of autism and epilepsy genes, offering potential therapeutic targets.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Researchers develop novel immunotherapy using modified brain cells to target Alzheimer's pathology directly in the brain.
Scientists develop pathway-selective drug that activates beneficial brain receptors while avoiding negative feedback loops.
